A randomized Phase II/III hepatitis B study of Hepalatide

Trial Profile

A randomized Phase II/III hepatitis B study of Hepalatide

Planning
Phase of Trial: Phase II/III

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Hepalatide (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Apr 2018 New trial record
    • 10 Apr 2018 According to an OmniComm Systems media release, Shanghai HEP Pharma will use TrialMaster EDC technology for this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top